LambdaVision, Inc.

10/13/2026

We’re heading back to space!

Today, LambdaVision is launching aboard SpaceX-35 to the International Space Station National Laboratory with our longtime partner Space Tango.

This flight marks our 10th ISS mission and continues our work to better understand how microgravity can improve the manufacturing processes behind our protein-based artificial retina.

Each mission brings new insights as we work toward more consistent, automated production and continue advancing our technology toward patients.

Nine Past ISS missions have built the foundation. Today, we continue building on it.

Check out the launch: https://www.youtube.com/live/f8FE2R7esZ0?si=POR-F7kMjC8Xc4Wj

10/01/2026

Today marks an exciting new chapter for LambdaVision.

After nine missions to the International Space Station, we are taking our first step beyond the ISS through our collaboration with Helogen.

This mission will allow us to study bacteriorhodopsin, the light-activated protein at the core of our artificial retina, in microgravity and gather insights that can help inform future space-based manufacturing.

Each mission brings us closer to understanding how low-Earth orbit can support the development and production of technologies designed to improve life here on Earth.

We’re proud of the LambdaVision team and grateful to the collaborators helping us take this next step.

09/27/2026

Today is World Retina Day, an opportunity to raise awareness of retinal degenerative diseases and recognize the patients, families, researchers, and clinicians impacted by them.

At LambdaVision, we’re working toward a future with new possibilities for patients through the development of our protein-based artificial retina. Earlier this month, Jordan Greco, Ph.D., and Sampriti Ramakrishnan traveled to Powered Research to advance our preclinical studies, marking an important step forward in that work.

We’re proud to be part of a global community working to advance retinal research and protect the gift of sight.

09/21/2026

LambdaVision is featured in a new Reuters article examining the future of pharmaceutical and biotechnology research and manufacturing in space.

Alongside companies including Merck, Auxilium Biotechnologies, Vast, Axiom Space, Starlab, and Varda Space Industries, the story highlights the growing work underway to explore the commercial potential of microgravity.

For LambdaVision, that includes nine missions to the International Space Station National Laboratory and our work using microgravity to advance the manufacturing process behind our protein-based artificial retina.

Read the full article: https://www.reuters.com/legal/litigation/drugmakers-prepare-next-phase-space-pharmaceuticals-iss-retirement-nears-2026-09-17/

As the International Space Station nears the end of ​its operational life, drugmakers are laying the groundwork for commercial pharmaceutical research and manufacturing in low Earth orbit, while working with regulators to establish rules for ‌producing medicines in space.

09/01/2026

We’re expanding our microgravity research!

LambdaVision is partnering with Helogen Corporation for an October mission that will mark our first flight beyond the ISS.

Using Helogen’s autonomous orbital platform, we’ll study bacteriorhodopsin, the light-activated protein used in our artificial retina and gather new data to inform future work in microgravity.

Building on nine missions to the ISS, this is an important next step as we explore new platforms for research and future commercial operations in low-Earth orbit.

Learn more: https://www.lambdavision.com/lambdavision-advances-space-based-manufacturing-with-its-first-mission-beyond-the-iss/

08/28/2026

Space-based biomanufacturing is moving closer to commercial reality, and LambdaVision is part of the story.

We’re proud to see LambdaVision and CEO Nicole Wagner, Ph.D., featured alongside leaders across the industry. The article highlights our nine missions to the International Space Station National Laboratory, the advantages we’ve observed manufacturing our artificial retinas in microgravity, and our plans to expand to new orbital platforms.

Thank you to Michael Greshko for taking a closer look at the opportunities, and challenges, shaping this emerging industry.

Read more: https://www.science.org/content/article/dreams-making-drugs-and-tissues-space-get-closer-reality

Maturing techniques and cheaper launches fuel microgravity research—and hopes of orbital manufacturing

08/17/2026

August is National Eye Exam Month.

Many eye diseases develop without noticeable symptoms, making routine eye exams an important part of protecting your long-term vision.

This month, make your eye health a priority by scheduling a comprehensive eye exam.

07/01/2026

July is Eye Injury Prevention Month!

Summer activities like mowing the lawn, playing sports, fishing, boating, and watching fireworks can increase the risk of eye injuries.

The good news? Many eye injuries are preventable with proper protective eyewear and a few simple safety measures.

At LambdaVision, we are working to develop a protein-based artificial retina for patients affected by retinal degenerative diseases, but protecting healthy vision remains just as important.

This month, make eye safety part of your summer routine and help keep your vision protected for years to come.

Learn more about our mission to restore meaningful vision: https://www.lambdavision.com/

06/23/2026

Happy International Women in Engineering Day from Team LambdaVision!

We are proud to recognize the women engineers and researchers driving innovation across biotechnology and space-based manufacturing. From advancing artificial retina development to pioneering new microgravity manufacturing techniques, their work is helping create solutions that could transform lives.

Thank you to the women helping build the future of science, engineering, and healthcare.

05/18/2026

NEWS: LambdaVision is partnering with Helogen Corporation to advance the future of scalable biomaterial manufacturing in low-Earth orbit.



This mission will mark LambdaVision’s first planned flight outside of the International Space Station and represents an important next step toward regulated, scalable production of our protein-based artificial retina in space.



Through 9 missions to the ISS, LambdaVision has demonstrated the feasibility of manufacturing 200-layer protein thin films in microgravity, where reduced gravity improves homogeneity, stability, and performance.



The collaboration with Helogen grew out of conversations initiated through Boryung’s Humans in Space challenge in 2023, highlighting the importance of building a global ecosystem to advance space-enabled healthcare and biotechnology innovation.



Read the full announcement: https://www.lambdavision.com/lambdavision-and-helogen-partner-to-advance-space-based-biomaterial-manufacturing/